Degeneration Process Leading to Alzheimer's Cracked by McGill Researchers
Author: McGill University
A research group has uncovered a critical process in understanding the degeneration of brain cells sensitive to Alzheimers disease.
Main DigestMcGill researchers crack degeneration process that leads to Alzheimer's - New study points to possible new therapeutic approaches in treatment of Alzheimer's Disease.
Alzheimer's Disease - Dementia is a loss of brain function that occurs with certain diseases. Alzheimer's disease (AD), is one form of dementia that gradually gets worse over time. It affects memory, thinking, and behavior. There are two types of AD: Early onset AD: Symptoms appear before age 60. This type is much less common than late onset. However, it tends to get worse quickly. Early onset disease can run in families. Several genes have been identified. Late onset AD: This is the most common type. It occurs in people age 60 and older. It may run in some families, but the role of genes is less clear.
A research group led by Dr. A. Claudio Cuello of McGill University's Faculty of Medicine, Dept. of Pharmacology and Therapeutics, has uncovered a critical process in understanding the degeneration of brain cells sensitive to Alzheimer's disease (AD).
The study, published in the February issue of the Journal of Neuroscience, suggests that this discovery could help develop alternative AD therapies.
A breakdown in communication between the brain's neurons is thought to contribute to the memory loss and cognitive failure seen in people with AD. The likely suspect is NGF (Nerve Growth Factor), a molecule responsible for generating signals that maintain healthy cholinergic neurons - a subset of brain cells that are particularly sensitive to AD - throughout a person's lifetime. Oddly, scientists had never been able to find anything wrong with this molecule to explain the degeneration of cholinergic neurons in patients with AD.
This new study, however, has elucidated the process by which NGF is released in the brain, matures to an active form and is ultimately degraded. The researchers were also able to determine how this process is altered in AD. The group demonstrated that treatment of healthy adult rats with a drug that blocks the maturation of active NGF leads to AD-like losses of cholinergic functional units, which result in cognitive impairments. By contrast, when treated with a drug to prevent degradation of active NGF, the numbers of cholinergic contacts increased significantly.
"Part of the difficulty in understanding this pathway has been due to the technical challenges associated with differentiating the active and inactive forms of NGF," explained Dr. Simon Allard, the study's lead author and a postdoctoral fellow at McGill. "Our proposed manipulations are different from existing therapies as they aim to protect neurons from degeneration."
The authors suggest that these findings may lead to pharmacological treatments that could delay the progression of Alzheimer's disease. "This discovery should help design alternative therapies," said Dr. Cuello, a Charles E. Frosst / Merck Chair.
This study was supported by the Canadian Institutes of Health Research (CIHR) and an endowment from Alan Frosst and the Frosst family.
- 1 - OCTA Eye Scan May Detect Sign of Early Alzheimer's Disease : American Academy of Ophthalmology (2018/11/03)
- 2 - How America Can Cope with Future Alzheimer's Epidemic : Silverado Senior Living (2010/10/19)
- 3 - Music Activates Regions of the Brain Spared By Alzheimer's Disease : University of Utah Health (2018/04/27)
- 4 - Link Between Vitamin D and Alzheimer's Disease : Thomas C. Weiss (2014/08/15)
- 5 - Importance of Family History for Onset of Alzheimer's Disease : McGill University (2018/02/26)
- 6 - New Criteria and Guidelines for the Diagnosis of Alzheimer's Disease : Alzheimer's Association (2011/04/19)
- 7 - DHA Fish Oil Supplements Do Not Slow Cognitive Decline in Alzheimer's : JAMA and Archives Journals (2010/11/03)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.
• Please report outdated or inaccurate information to us.